Randolf Kerschbaumer
Co-Founder, President & Chief Executive Officer OncoOne
Seminars
Wednesday 2nd December 2026
Breaking the Preclinical-to-Clinical Bottleneck: Advancing Novel Theranostic Radiopharmaceuticals into First-in-Human Trials
12:00 pm
- Navigating the transition from a completed preclinical package into first-in-human development, identifying the critical hurdles that emerge as novel theranostic programmes approach the clinic
- Coordinating clinical, CMC and regulatory requirements to build a cohesive translational strategy and avoid delays between preclinical completion and patient dosing
- Applying lessons learned from preparing an early-stage radiopharmaceutical programme for Phase I to anticipate translational challenges earlier and accelerate novel theranostics towards patients
Wednesday 2nd December 2026
Re-Engineering the Therapeutic Window: Can Pre-Targeting Overcome the Fundamental Limitations of Conventional Radiopharmaceuticals?
1:30 pm
- Examining how the pharmacokinetic coupling of tumor targeting and radionuclide delivery constrains the therapeutic window of conventional radiopharmaceuticals
- Exploring how pre-targeting separates tumor localization from radionuclide administration to improve tumor-to-non-tumor tissue exposure and enable more flexible radionuclide delivery
- Sharing lessons learned from candidate selection, platform optimization, and preclinical development in advancing next-generation pre-targeting technologies
- Identifying the target characteristics and disease settings most likely to benefit from pre-targeting and unlock previously inaccessible therapeutic opportunities